

## **API PRODUCT LIST**





# REACHING PEOPLES TOUCHING LIVES

From humble beginnings in 1983, Sun Pharma has grown to become the 4 largest speciality generic pharmaceutical company in the world. Our passion for R&D has enabled us to develop over 2000 products that are sold in over 100 countries worldwide. At Sun, we are driven by our core values of quality, reliability, innovation, trust and consistency. These values inspire us to reach out and touch millions of lives globally.

#### **ABOUT US**

Sun Pharma is the 4<sup>th</sup> largest generic pharmaceutical company in the world and ranks #1 in India. A vertically integrated busines with economies of scale and an extremely skilled team enables timely delivery of quality products at affordable prices. It serves customers and patients in over 100 countries across the globe. Sun Pharma's global presence is supported by 43 manufacturing facilities spread across 5 continents with a multi-cultural workforce comprising over 50+ nationalities.

The consolidated revenues for 12 months ending Sep 2022 are US\$ 5 billion, of which USA contributes US\$ 1.5 billion. In India, the company enjoys leadership across 10 different therapeutic classes of doctors. Sun Pharma's 33 brands feature amongst the top 300 pharmaceutical brands in India. It's footprint across emerging markets covers over 100 markets including 6 markets in Western Europe. It's Global Consumer Healthcare business is ranked in the Top 10 across 4 global markets. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities with 2,000 scientists and R&D investments of over 5.8% of net sales.

Sun Pharma's product list includes complex APIs that require isolated manufacturing area like anti-cancers, peptides, steroids, sex hormones and controlled/narcotic substances. It offers Bulk Actives, Intermediates and services for Custom Synthesis. Every year, the company makes a large number of products filings based on the technology developed at its R&D centres. Sun Pharma manufactures APIs in 14 world class manufacturing plants located in India, Hungary, the US, Australia and Israel. These manufacturing facilities are CGMP compliant and hold approvals from global regulatory agencies including USFDA, EUGMP, PMDA, COFEPRIS, TGA, etc.

The company currently has 426 DMF/CEP filed, of which 321 have been approved as on June 2022.

Sun Pharma's comprehensive end to end support ensures smooth development, timely filing and successful launch of products. Its R&D prowess and manufacturing capabilities are strengthened by a strong and well informed regulatory team. It has an experienced team of IP attorneys and other skilled professionals, specialising in medicinal chemistry and IP law who protect its IP wealth. This team ensures that all the API and processes developed for global markets comply with applicable laws and intellectual properties.

With its vision of Reaching People and Touching Lives globally and as a leading provider of valued medicines, Sun Pharma is dedicated to bring about change and create a meaningful impact in the lives of others.



Numbers as of September 30, 2022



Product	Therapeutic Category	Specs	CAS No.	DMF Status
Abaloparatide	Anti-Osteoporosis	PN	[247062-33-5]	
Afatinib Dimaleate	Anti-Cancer	PN	[850140-73-7]	<b>A</b>
Alectinib Hcl	Anti-Cancer	PN	[1256580-46-7]	
Ambrisentan	Anti-Hypertensive	USP	[177036-94-1]	
Apixaban	Anti-Coagulant	PN	[503612-47-3]	<b>A</b>
Apomorphine	Dopamine D2 Agonist	PN	[943319-70-8]	
Apremilast	Anti-Psoriatic	PN	[608141-41-9]	
Bempedoic Acid	Lowering LDL Cholesterol	PN	[738606-46-7]	
Bortezomib	Anti-Cancer	PN	[179324-69-7]	<b>A</b> •
Bosentan Monohydrate	Cardiovascular	PN	[157212-55-0]	<b>A</b> • •
Bosutinib	Anti-Cancer	PN	[380843-75-4]	
Brivaracetam	Anti-Epileptic	PN	[357336-20-0]	
Cabozantinib S-Malate	Anti-Cancer	PN	[1140909-48-3]	
Canagliflozin	Anti-Diabetic	PN	[842133-18-0]	<b>A</b>
Carfilzomib	Anti-Cancer	PN	[868540-17-4]	
Cariprazine Hcl	Anti-Depressant	PN	[1083076-69-0]	<b>A</b>

JDMF

Korean DMF

Canadian DMF

CEP

**▲** USDMF

<sup>\*</sup> New Products are offered for R&D Purpose

<sup>•</sup> PN - Producer's Norms

<sup>•</sup> All transactions are carried out in conformity with the patent laws applicable in the user country Responsibility with respect to third party's patent rights in a specific country lies exclusively with the Buyer



Product	Therapeutic Category	Specs	CAS No.	DMF Status
Colestipol Hcl	Calcimimetic	PN	[226256-56-0]	<b>A</b>
Dalfampridine	Multiple Sclerosis	PN	[45498-20-2]	<b>A</b>
Dapagliflozin	Anti-Diabetic	PN	[461432-26-8]	<b>A</b>
Dasatinib Monohydrate	Anti-Cancer	PN	[302962-49-8]	<b>A</b>
Dimethyl Fumarate	Multiple Sclerosis	PN	[624-49-7]	<b>A</b>
Doxercalciferol	Hyperparathyroidism	PN	[54573-75-0]	<b>A</b>
Edaravone	Neuroprotective	USP	[89-25-8]	
Elagolix Sodium	Anti-Gonadotrophin	PN	[832720-36-2]	<b>A</b>
Eluxadoline	Gastrointestinal	PN	[864821-90-9]	<b>A</b>
Empagliflozin	Anti-Diabetic	PN	[864070-44-0]	<b>A</b>
Enzalutamide	Anti-Cancer	PN	[915087-33-1]	
Epoprostenol Sodium	Permolary Arterial	PN	[61849-14-7]	<b>A</b> •
Erlotinib Hcl	Anti-Cancer	PN	[183319-69-9]	<b>A</b> *
Faropenem Na	Antibiotic	PN	[106560-14-9]	
Fulvestrant	Anti-Cancer	EP/USP	[129453-61-8]	•

JDMF

CEP

**▲** USDMF

**EDMF** 

Canadian DMF

<sup>\*</sup> New Products are offered for R&D Purpose

<sup>•</sup> PN - Producer's Norms

<sup>•</sup> All transactions are carried out in conformity with the patent laws applicable in the user country Responsibility with respect to third party's patent rights in a specific country lies exclusively with the Buyer



Product	Therapeutic Category	Specs	CAS No.	DMF Status
Ibrutinib	Anti-Cancer	PN	[936563-96-1]	<b>A</b>
Icatibant Acetate	Hereditary Angioedma	PN	[138614-30-9]	<b>A</b>
Isavuconazonium Sulfate	Anti-Fungal	PN	946075-13-4	
Ivacaftor	Cystic Fibrosis	PN	[873054-44-5]	<b>A</b>
Lanreotide Acetate	Somatostatin Analog	USP	[127984-74-1]	
Lenalidomide	Anti-Cancer	PN	[191732-72-6]	<b>A</b>
Lenvatinib Mesylate	Anti-Cancer	USP	[857890-39-2]	<b>A</b>
Levalbuterol Hcl / Tartrate	Anti-Asthmatic	PN	[50293-90-8]	<b>A</b>
Linaclotide	Irritable Bowel Syndrome	PN	[851199-59-2]	<b>A</b>
Liothyronine Sodium	Hormone Replacement	USP/EP	[55-06-1]	<b>A</b>
Lumateperone	Anti-Psychotic	PN	1187020-80-9	
Lurasidone Hcl	Anti-Psychotic	PN	[367514-88-3]	<b>^</b>
Methylnaltrexone Bromide	Opiod Receptor Anatgonist	PN	[73232-52-7]	
Nadifloxacin	Anti-Bacterial	JP	[124858-35-1]	<b>A</b>
Nilotinib Hcl	Anti-Cancer	PN	[923288-90-8]	
▲ USDMF ■ CEP	● EDMF <b>*</b> JDMF	• Kor	ean DMF •	Canadian DMF

<sup>\*</sup> New Products are offered for R&D Purpose

<sup>•</sup> PN - Producer's Norms

<sup>•</sup> All transactions are carried out in conformity with the patent laws applicable in the user country Responsibility with respect to third party's patent rights in a specific country lies exclusively with the Buyer



Product	Therapeutic Category	Specs	CAS No.	DMF Status
Nintedanib Esylate	Idiopathic Pulmonary Fibrosis	PN	[656247-17-5]	
Niraparib Tosylate	Anti-Cancer	PN	[1038915-73-9]	
Norepinephrine Bitartrate	Anti-Hypotensive	USP/EP	[108341-18-0]	
Olaparib	Anti-Cancer	PN	[763113-22-0]	
Palbociclib	Anti-Cancer	PN	[571190-30-2]	<b>A</b>
Paliperidone Palmitate	Anti-Psychotic	PN	[199739-10-1]	<b>A</b>
Pazopanib Hcl	Anti-Cancer	PN	[635702-64-6]	
Pentetreotide	Radiodiagnostic Agent	USP	[138661-02-6]	
Pimavaserin Tartrate	Anti-Parkinson	PN	[706782-28-7]	
Plecanatide	Irritable Bowel Syndrome	PN	[467426-54-6]	
Ponatinib	Anti-Cancer	PN	[943319-70-8]	
Pramlintide Acetate	Anti-Diabetic	PN	[196078-30-5]	<b>A</b>
Prucalopride	Laxative	USP	[179474-81-8]	
Regadenoson	Stress Agent	PN	[313348-27-5]	<b>A</b>
Safinamide	Anti-Parkinson	PN	[133865-89-1]	

**#JDMF** 

CEP

**▲** USDMF

EDMF

Canadian DMF

<sup>\*</sup> New Products are offered for R&D Purpose

<sup>•</sup> PN - Producer's Norms

<sup>•</sup> All transactions are carried out in conformity with the patent laws applicable in the user country Responsibility with respect to third party's patent rights in a specific country lies exclusively with the Buyer



Product	Therapeutic Category	Specs	CAS No.	DMF Status
Selenious Acid	Anti-Oxidant	USP	[7783-00-8]	
Semaglutidet	Anti-Diabetic	USP	[910463-68-2]	
Silodosin	ВРН	JP	[160970-54-7]	
Sincalide	Contrast Media	USP	[25126-32-3]	
Sitagliptin Phosphate	Anti-Diabetic	BP/USP	[654671-77-9]	<b>A</b>
Sonidegib	Anti-Cancer	PN	[956697-53-3]	
Sunitinib Malate	Anti-Neoplastics	PN	[341031-54-7]	<b>A</b>
Tafamidis	Cardiovascular	USP	[594839-88-0]	
Ticagrelor	Coagulation Inhibitors	IP/EP	[274693-27-5]	
Tirzepatide	Anti-Diabetic	PN	[[2023788-19-2]	
Tofacitinib citrate	Rheumatoid Arthritis	IP	[540737-29-9]	
Tolvaptan	Metabolic Disorders	PN	[81846-19-7]	
Trazodone Hcl	Anti-Depressant	PN	[19794-93-5]	

JDMF

Korean DMF

Canadian DMF

* New Products	are	offered	for	R&D	Purpose

CEP

**▲** USDMF

<sup>•</sup> PN - Producer's Norms

<sup>•</sup> All transactions are carried out in conformity with the patent laws applicable in the user country Responsibility with respect to third party's patent rights in a specific country lies exclusively with the Buyer



Product	Therapeutic Category	Specs	CAS No.	DMF Status
Abiraterone Acetate	Anti-Cancer	PN	[154229-18-2]	<b>^</b>
Amisulpride	Anti-Psychotic	EP	[71675-85-9]	•
Anastrozole	Anti-Cancer	EP	[120511-73-1]	<b>A</b> • •
Atorvastatin Calcium	Cardiovascular	USP/EP	[134523-03-8]	<b>A</b> • •
Bicalutamide	Anti-Androgen	EP/USP	[90357-06-5]	• • •
Budesonide	Anti-Inflammatory	EP/USP	[51333-22-3]	<b>A</b>
Buprenorphine Base & Hcl	Pain Management	EP/USP	[52485-79-7]	<b>A</b> • •
Carbamazepine	Seizure Disorders	EP/USP	[298-46-4]	
Candesartan Cilexetil	Cardiovascular	EP/USP	[145040-37-5]	•
Capecitabine	Anti-Cancer	USP	[154361-50-9]	<b>A</b> • • •
Carboplatin	Anti-Cancer	EP/USP	[41575-94-4]	<b>A</b>
Carvedilol	Cardiovascular	EP/USP	[72956-09-3]	<b>A</b>
Cefuroxime Axetil	Antibiotic	EP/USP	[64544-07-6]	•
Cilastatin Sodium - Sterile	Anti-Infective	EP/USP	[81129-83-1]	•
Cisplatin	Anti-Cancer	EP/USP	[15663-27-1]	•

JDMF

CEP

**▲** USDMF

EDMF

Canadian DMF

<sup>\*</sup> New Products are offered for R&D Purpose

<sup>•</sup> PN - Producer's Norms

<sup>•</sup> All transactions are carried out in conformity with the patent laws applicable in the user country Responsibility with respect to third party's patent rights in a specific country lies exclusively with the Buyer



Product	Therapeutic Category	Specs	CAS No.	DMF Status
Clarithromycin Granules	Anti-Infective	EP/USP	[81103-11-9]	•
Clomipramine Hcl	Anti-Depressant	EP/USP	[17321-77-6]	<b>A</b> •
Clonazepam	Anti-Epileptic	EP/USP	[1622-61-3]	<b>A</b> •
Deferasirox	Iron Chelator	PN	[201530-41-8]	<b>A</b>
Desloratadine	Anti-Histamine	EP	[100643-71-8]	
Divalproex Sodium	Anti-Epileptic	USP	[76584-70-8]	<b>A</b> •
Donepezil Hcl	Anti-Alzheimer	USP	[120011-70-3]	•
Doripenem -Sterile	Anti-Bacterial	PN	[364622-82-2]	
Ertapenem Sodium	Anti-Bacterial	PN	[153773-82-1]	<b>A</b>
Esomeprazole Sodium	Proton Pump Inhibitor	PN	[161796-78-7]	<b>A • •</b>
Flurbiprofen / S-Flurbiprofen	NSAID	PN	[62288-83-9]	
Fluticasone Propionate	Anti-Inflammatory	EP/USP	[80474-14-2]	<b>A</b> •
Fluvastatin Sodium	Cardiovascular	EP	[93957-55-2]	•
Fluvoxamine Maleate	Anti-Depressant	EP/USP	[61718-82-9]	<b>A</b> * •
Gemcitabine Hcl	Anti-Cancer	EP/USP	[122111-03-9]	▲ ■ *
	ı		1	-

JDMF

Korean DMF

Canadian DMF

CEP

**▲** USDMF

<sup>\*</sup> New Products are offered for R&D Purpose

<sup>•</sup> PN - Producer's Norms

<sup>•</sup> All transactions are carried out in conformity with the patent laws applicable in the user country Responsibility with respect to third party's patent rights in a specific country lies exclusively with the Buyer



Product	Therapeutic Category	Specs	CAS No.	DMF Status
Hydroxyprogesterone Caproate	Steroidal Progestin	PN	[630-56-8]	<b>A</b>
Irinotecan Hcl Trihydrate	Anti-Cancer	PN	[136572-09-3]	<b>A</b> •
Imatinib Mesylate	Anti-Cancer	PN	[220127-57-1]	<b>A • •</b>
Imipenem - Sterile	Anti-Bacterial	EP/USP	[74431-23-5]	•
Isotretinoin	Anti-Acne	EP/USP	[4759-48-2]	<b>A</b> • •
Letrozole	Anti-Cancer	EP	[112809-51-5]	<b>A</b>
Leuprolide Acetate	Anti-Cancer	PN	[74381-53-6]	<b>A</b>
Loteprednol Etabonate	Anti-Allergy	PN	[82034-46-6]	<b>^</b>
Magnesium Valproate	Anti-Epileptic	PN	[62959-43-7]	•
Meloxicam	NSAID	EP/USP	[71125-38-7]	• • •
Meropenem Buffer / Sterile	Anti-Bacterial	EP/JP/USP	[119478-56-7]	
Mesalamine	Anti-Inflammatory	EP/USP	[89-57-6]	<b>4</b> • •
Methylphenidate Hcl	CNS Stimulant	EP	[298-59-9]	•
Metoprolol Succinate	Anti-Hypertensive	EP/USP	[98418-47-4]	<b>A</b> • •
Metoprolol Tartrate	Anti-Hypertensive	EP/USP	[56392-17-7]	<b>A</b> • •

JDMF

CEP

**▲** USDMF

EDMF

Canadian DMF

<sup>\*</sup> New Products are offered for R&D Purpose

<sup>•</sup> PN - Producer's Norms

<sup>•</sup> All transactions are carried out in conformity with the patent laws applicable in the user country Responsibility with respect to third party's patent rights in a specific country lies exclusively with the Buyer



Product	Therapeutic Category	Specs	CAS No.	DMF Status
Midazolam Base	Anti-Anxiety	EP/USP	[59467-70-8]	•
Mirtazapine	Anti-Depressant	PN	[85650-52-8]	<b>A</b>
Naloxone Hcl	Opioid Antagonist	EP/USP	[357-08-4]	<b>A</b>
Naltrexone Hcl	Opioid Antagonist	EP/USP	[16676-29-2]	<b>A</b> •
Octreotide Acetate	Anti-Cancer	USP	[79517-01-4]	<b>A</b> • *
Ofloxacin Hcl	Anti-Infective	EP/USP	[82419-36-1]	•
Olanzapine (Form-I)	Anti-Psychotic	EP/USP	[132539-06-1]	•
Ondansetron Base / Hcl	Anti-Emetic	USP	[116002-70-1]	<b>A</b> • • •
Orlistat	Anti-Obesity	PN/USP	[96829-58-2]	A • • •
Oxaliplatin	Anti-Cancer	EP/USP	[61825-94-3]	<b>A</b> • *
Oxcarbazepine	Anti-Epileptic	EP/USP	[28721-07-5]	<b>A</b>
Oxetacaine	Potent Local Anesthetic	PN	[126-27-2]	
Pantoprazol Sodium Sesquihydrate	Proton Pump Inhibitor	EP	[164579-32-2]	• •
Pentoxifylline	Anti-Anginal	EP/USP	[6493-05-6]	<b>A</b>
Phentermine Hcl	Appetite Suppressant	USP	[1197-21-3]	•
USDMF CEP	● EDMF <b> *</b> JDMF	→ Kor	rean DMF	Canadian DMF

<sup>\*</sup> New Products are offered for R&D Purpose

<sup>•</sup> PN - Producer's Norms

<sup>•</sup> All transactions are carried out in conformity with the patent laws applicable in the user country Responsibility with respect to third party's patent rights in a specific country lies exclusively with the Buyer



Product	Therapeutic Category	Specs	CAS No.	DMF Status
Quetiapine Fumarate	Anti-Psychotic	PN	[111974-72-2]	<b>A</b> •
Ranolazine	Anti-Anginal	PN	[95635-55-5]	<b>A</b> •
Rosuvastatin Calcium	Cardiovascular	EP/USP	[147098-20-2]	<b>A</b>
Sertraline Hcl	Anti-Depressant	EP	[79559-97-0]	•
Sodium Valproate	Anti-Epileptic	EP/USP	[1069-66-5]	<b>A</b> • •
Tamsulosin Hcl/Pellets	Benign Prostatic Hyperplasia	EP/USP	[106463-17-6]	<b>A</b> •
Temozolomide	Anti-Cancer	USP	[85622-93-1]	<b>A • • •</b>
Testosterone Cypionate / Salts	Hormone Replacement	EP/USP	[58-20-8]	<b>A</b>
Tetrabenazine	Anti-Psychotic	PN	[58-46-8]	•
Tizanidine Hcl	Muscle Relaxant	USP	[64461-82-1]	<b>A</b> • •
Topiramate	Anti-Epileptic	USP	[97240-79-4]	<b>A • • •</b>
Tramadol Hcl	Opioid Analgesic	EP/USP	[36282-47-0]	<b>A</b> • • •
Valganciclovir Hcl	Anti-Viral	PN	[175865-59-5]	•
Valaciclovir	Anti-Viral	EP/USP	[124832-27-5]	•
Valproic Acid	Anti-Epileptic	EP/USP	[99-66-1]	<b>A</b> •
Zonisamide	Anti-Epileptic	USP	[68291-97-4]	<b>A</b>
Zolpidem Tartrate	Hypnotic	EP/USP	[99294-93-6]	

JDMF

CEP

**▲** USDMF

EDMF

Canadian DMF

<sup>\*</sup> New Products are offered for R&D Purpose

<sup>•</sup> PN - Producer's Norms

<sup>•</sup> All transactions are carried out in conformity with the patent laws applicable in the user country Responsibility with respect to third party's patent rights in a specific country lies exclusively with the Buyer



## **ALKALOIDA PRODUCTS**

Product	Therapeutic Category	Specs	CAS No.	DMF Status
Acenocoumarol	Anti-Coagulant	ВР	[152-72-7]	•
Buspirone HCI	Anxiolytics	EP/USP	[33386-08-2]	
Codeine Base	Analgesic	BP/EP	[6059-47-8]	
Codeine Phosphate Hemihydrate	Analgesic	BP/EP/USP	[41444-62-6]	•
Dihydrocodeine Hydrogentartrate Tartrate	Analgesic	BP/EP	[5965-13-9]	•
Hydroxychloroquine Sulphate	Anti-Malarial	USP	[747-36-4]	<b>A</b>
Noscapine Base	Anti-Tussive	BP/EP	[128-62-1]	•
Noscapine Hcl	Anti-Tussive	BP/EP	[912-60-7]	•
Oxycodone Hcl	Analgesic	EP	[124-90-3]	•
Phenobarbital Acid	Anti-Epileptic	BP/EP/USP	[50-06-6]	<b>A</b> • •
Phenobarbital Sodium	Anti-Epileptic	BP/EP	[57-30-7]	<b>A</b>
Pholcodine Monohydrate	Anti-Tussive	BP/EP	[509-67-1]	•

▲ USDMF ■ CEP ● EDMF	Korean DMF	Canadian DMF
----------------------	------------	--------------

<sup>\*</sup> New Products are offered for R&D Purpose

<sup>•</sup> PN - Producer's Norms

<sup>•</sup> All transactions are carried out in conformity with the patent laws applicable in the user country Responsibility with respect to third party's patent rights in a specific country lies exclusively with the Buyer



#### **CHATTEM PRODUCTS**

Product	Therapeutic Category	Specs	CAS No.	DMF Status
D-Amphetamine Base	CNS Simulant	PN	[51-64-9]	<b>A</b>
D-Amphetamine Sulfate	CNS Simulant	USP	[51-63-8]	<b>A</b>
DL-Amphetamine Sulfate	CNS Simulant	PN	[60-13-9]	<b>A</b>
D-Amphetamine Saccharate	CNS Simulant	PN	[300666-47-1]	
DL-Amphetamine Aspartate	CNS Simulant	PN	[25333-81-7]	
Ammonium Lactate	Topical Skin Use	USP	[515-98-0]	<b>A</b>
Benzphetamine Hcl	Weight Loss	PN	[5411-22-3]	<b>A</b>
Buprenorphine Hcl	Pain Management	PN	[53152-21-9]	
Butalbital	Depressant	USP	[77-26-9]	<b>A</b> •
Butabarbital Base	CNS Depressant	USP	[125-40-6]	
Butabarbital Sodium	CNS Depressant	USP	[143-81-7]	<b>A</b>
Calcium Oxybate	Anti-Coagulant	PN	[82316-97-0]	
Codeine Phosphate	Pain Management	PN	[52-28-8]	
Dihydrocodeine Bitartrate	Pain Management	PN	[5965-13-9]	<b>A</b>
Fentanyl Base	Pain Management	USP/EP/IP	[437-38-7]	<b>A</b>

JDMF

Korean DMF

CEP

**▲** USDMF

EDMF

Canadian DMF

<sup>\*</sup> New Products are offered for R&D Purpose

<sup>•</sup> PN - Producer's Norms

<sup>•</sup> All transactions are carried out in conformity with the patent laws applicable in the user country Responsibility with respect to third party's patent rights in a specific country lies exclusively with the Buyer



#### **CHATTEM PRODUCTS**

Product	Therapeutic Category	Specs	CAS No.	DMF Status
Fentanyl Citrate	Pain Management	USP/EP/IP	[990-73-8]	<b>A</b>
Glycine	Used in IV Solutions	USP/EP	[56-40-6]	<b>A</b>
Hydrocodone Bitartrate	Pain Management	USP	[143-71-5]	<b>A</b>
Hydromorphone Hcl	Pain Management	USP	[71-68-1]	<b>A</b>
Hydroxyamphetamine HBr	Ophthalmic Solution	USP	[306-21-8]	<b>A</b>
Levmetamphetamine	Vasoconstrictor	USP	[33817-09-03]	
Levorphanol	Pain Management	PN	[77-07-6]	
Lisdexamphetamine Dimesylate	CNS Simulant	PN	[608-137-33-3]	<b>A</b>
Methamphetamine Hcl	CNS Simulant	USP	[51-57-0]	
Methylphenidate Base	CNS Simulant	USP/EP	[113-45-1]	<b>A</b>
Methylphenidate Hcl	CNS Simulant	USP	[298-59-9]	<b>A</b>
D-Methylphenidate Base	CNS Simulant	USP	[40421-64-9]	
D-Methylphenidate Hcl	CNS Simulant	USP	[19262-68-1]	<b>A</b>
Methenamine	Anti-Bacterial	USP	[100-97-0]	
Methenamine Mandelate	Anti-Bacterial	USP	[587-23-5]	
	'	'		

JDMF

Korean DMF

Canadian DMF

CEP

**▲** USDMF

<sup>\*</sup> New Products are offered for R&D Purpose

<sup>•</sup> PN - Producer's Norms

<sup>•</sup> All transactions are carried out in conformity with the patent laws applicable in the user country Responsibility with respect to third party's patent rights in a specific country lies exclusively with the Buyer



#### **CHATTEM PRODUCTS**

Product	Therapeutic Category	Specs	CAS No.	DMF Status
Oxycodone Hcl	Pain Management	USP/EP	[124-90-3]	<b>A</b>
Oxymorphone Hcl	Pain Management	USP	[357-07-3]	
Oripavine	Pain Management	PN	[467-04-9]	
Pamabrom	Diuretic	USP	[606-04-2]	
Sodium Oxybate	CNS Stimulant	PN	[502-85-2]	
Thebaine	Pain Management	PN	[115-37-7]	

\* New Products are offered for R&D Purpose

CEP

**▲** USDMF

EDMF

JDMF

Canadian DMF

<sup>•</sup> PN - Producer's Norms

<sup>•</sup> All transactions are carried out in conformity with the patent laws applicable in the user country Responsibility with respect to third party's patent rights in a specific country lies exclusively with the Buyer



#### SUN AUSTRALIA PRODUCTS

Product	Therapeutic Category	Specs	CAS No.	DMF Status
Codeine	Narcotic Raw Material	PN	[76-57-3]	
Codeine Phosphate Hemihydrate	Analgesic	EP/USP	[41111-62-6]	
Morphine	Narcotic Raw Material	PN	[57-27-2]	
Noscapine	Anti-Tussive	PN	[128-62-1]	
Oripavine	Narcotic Raw Material	PN	[467-04-9]	
Thebaine	Narcotic Raw Material	PN	[115-37-7]	
Ethiodised Oil	Pain Management	PN	[8008-53-5]	
CBD	Pain Management	PN	[13956-29-1]	
THC	Pain Management	PN	[1972-08-3]	

JDMF

Korean DMF

Canadian DMF

▲ USDMF ■ CEP

\* New Products are offered for R&D Purpose

• All transactions are carried out in conformity with the patent laws applicable in the user country Responsibility with respect to third party's patent rights in a specific country lies exclusively with the Buyer

<sup>•</sup> PN - Producer's Norms





























- **★** GLOBAL HEADQUARTERS
- **A** R&D CENTERS
- API & FORMULATION PLANTS
- API PLANTS
- FORMULATION PLANTS







#### Sun Pharmaceutical Industries Ltd.

Sun House, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai 400063 India, Tel: 022 4324 1234

Email: apimarketing@sunpharma.com www.sunpharma.com | #wearesun